InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Discover the detailed record of transactions filed by Javitt Jonathan C, Chief Executive Officer. Insider active across 1 companies, notably NRX Pharmaceuticals, Inc.. Aggregated, 9 filings have been recorded. Total volume traded: €5.7m. The latest transaction was disclosed on 3 June 2022 — Cession. Regulator: SEC (Form 4). The full history is openly available.
Declarations9 total
€159,149243,596 shares@ €0.6533100.0% of flow
Common Stock
SEC:0000880984-22-000007:0·
€5m100,000 shares@ €54.438899.0% of flow
Common Stock
SEC:0000921895-22-001872:0·
Ideal exit: 26 Feb 2023 (T+270)
€54,439100,000 shares@ €0.54441.0% of flow
Common Stock
SEC:0000921895-22-001874:0·
Ideal exit: 26 Feb 2023 (T+270)
434,594 shares
Common Stock
SEC:0000950142-21-003505:0·
434,594 shares
Common Stock
SEC:0000950142-21-003505·
13,971,864 shares
Common Stock
SEC:0000950142-21-001944·
46,332 shares
Common Stock
SEC:0000950142-21-001945·
13,971,864 shares
Common Stock
SEC:0000950142-21-001944:0·
46,332 shares
Common Stock
SEC:0000950142-21-001945:0·
9 of 9 declarations
About Javitt Jonathan C
Jonathan C. Javitt is the Chief Executive Officer and Chief Scientist of NRX Pharmaceuticals, Inc. In this role, he oversees the company's operations and research initiatives. His expertise in life sciences is essential for guiding the development of new therapies. As CEO, he plays a key role in the overall strategy and direction of the company.
